Alterity Therapeutics and the U.S. Food and Drug Administration (FDA) have reached an agreement regarding the Phase 3 clinical program for ATH434 in treating Multiple System Atrophy (MSA). This regulatory alignment establishes the framework for the company's pivotal late-stage clinical development plan. Alterity Therapeutics is a biotechnology company focused on developing therapies for neurodegenerative diseases.
